TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates Accessibility StatementSkip NavigationTheravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS EnrollmentNEW YORK, March 25, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encourage ...